Pine Brook, NJ (USA) and Basel (Switzerland) -- Elusys Therapeutics and Lonza today announced an agreement for the scale-up and commercial production of Anthim®, a therapeutic monoclonal antibody in late-stage development for the treatment of inhaled anthraxUnder the new contract, Lonza will p

read more>>

LOUISVILLE, KY -- This week at ICAD 2010, Neuronetrix for the first time publicly demonstrated their COGNISION™ System, an innovative platform which enables objective assessment of cognitive functionThe demonstration focused on the COGNISION™ System's ability, using a non-invasive tech

read more>>

ALLSCHWIL, SWITZERLAND and MARSEILLE, FRANCE -- Actelion Ltd (SIX: ATLN) and privately-held Trophos SA announced today that they have entered into a binding agreement whereby Actelion has, for EUR 10 million, obtained an exclusive option to acquire privately-held Trophos SA, a clinical stage Troph

read more>>

ATLANTA -- The American Society for Radiation Oncology (ASTRO) has accepted four abstracts from users of Elekta Stereotactic Body Radiation Therapy (SBRT) technology on the use of SBRT to treat non-small cell lung cancer (NSCLCThe clinicians will present their findings during presentations at ASTR

read more>>

Vancouver, BC -- Tekmira Pharmaceuticals Corporation (TSX: TKM), a leader in RNA interference (RNAi) therapeutics, today announced that it has been awarded a new contract with the United States Department of Defense (DoD) Chemical and Biological Defense Program (CBDP) through the U.S. Army Space M

read more>>

Novato, California -- Just 16 months after the Kakkis EveryLife Foundation kicked off the CureTheProcess Campaign, the Foundation, in association with the National Organization of Rare Diseases (NORD) and numerous other patient and physician organizations, have increased the support and commitment

read more>>

BOTHELL, WA -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, yesterday filed a current report on Form 8-K with the U.S. Securities and Exchange Commission providing the following disclosureOn July 14, 2010, AVI BioPharma, Inc. (the "Company") was awarded a new contract

read more>>

BOTHELL, WA -- AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced upcoming presentations on AVI-4658, the Company's exon skipping therapy for the treatment of Duchenne muscular dystrophy, at the XII International Congress on Neuromuscular Diseases taking place July

read more>>

THOUSAND OAKS, Calif. -- Amgen (Nasdaq: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review designation to denosumab, a subcutaneous RANK Ligand inhibitor, for the treatment of bone metastases to reduce skeletal related events (SREs) in patients with

read more>>

Scott & White's Cancer Research Institute (CRI) is conducting a clinical trial that targets malignant T-cell lymphoma, a type of blood cancerLymphoma, which affects the white blood cells that normally protect against illness, is categorized either as B-cell or T-cell. About 85% of lymphomas ar

read more>>